Combining Two FDA-Approved Drugs May Be Harmful for Patients with Metastatic Melanoma

Add a Comment By Media Staff   |  Thursday, April 4, 2013 Early research led by investigators at Memorial Sloan-Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

Visit site:
Combining Two FDA-Approved Drugs May Be Harmful for Patients with Metastatic Melanoma

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share